Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondary Resistance”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07641049
What this trial is testing

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSCA-positive Prostate Cancer+1 more
Beijing Biotech 36
Not applicableLooking for participantsNCT06717243
What this trial is testing

Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

Who this might be right for
Small Cell Lung CancerLarge Cell Neuroendocrine (NE) TumorsTreatment Failure+3 more
Oncology Center of Biochemical Education And Research 111
Testing effectiveness (Phase 2)Ended earlyNCT02656615
What this trial is testing

Abiraterone-Rechallenge Study for CRPC Patients

Who this might be right for
Prostate Cancer
Aurelius Omlin 4
Testing effectiveness (Phase 2)Temporarily pausedNCT06200103
What this trial is testing

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Mayo Clinic 236
Testing effectiveness (Phase 2)Ended earlyNCT02203513
What this trial is testing

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Ovarian CancerBreast CancerProstate Cancer
National Cancer Institute (NCI) 111
Not applicableUnknownNCT05051592
What this trial is testing

Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
National University Hospital, Singapore 40
Early research (Phase 1)Study completedNCT05252364
What this trial is testing

Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Hinova Pharmaceuticals Aus Pty Ltd 22
Testing effectiveness (Phase 2)WithdrawnNCT00149032
What this trial is testing

Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host

Who this might be right for
Hematological MalignancyNeoplasm Metastasis
Hadassah Medical Organization 50
Testing effectiveness (Phase 2)Looking for participantsNCT06039371
What this trial is testing

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
University of Washington 69
Testing effectiveness (Phase 2)Study completedNCT03899467
What this trial is testing

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Suzhou Kintor Pharmaceutical Inc, 61
Not applicableLooking for participantsNCT07347600
What this trial is testing

Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Hoffmann-La Roche 500
Testing effectiveness (Phase 2)Ended earlyNCT00265200
What this trial is testing

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

Who this might be right for
Carcinoma, Non-Small Cell LungCarcinoma, Small Cell LungMetastases
University of Louisville 28
Testing effectiveness (Phase 2)Looking for participantsNCT06228053
What this trial is testing

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Syntrix Biosystems, Inc. 53
Early research (Phase 1)Study completedNCT03575819
What this trial is testing

FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Fortis Therapeutics, Inc. 56
Testing effectiveness (Phase 2)Ended earlyNCT01703065
What this trial is testing

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateCastration-resistant Prostate CancerRecurrent Prostate Cancer+2 more
University of Washington 9
Testing effectiveness (Phase 2)WithdrawnNCT01750866
What this trial is testing

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Who this might be right for
Castrate-resistant Metastatic Prostate Cancer
Case Comprehensive Cancer Center
Not applicableLooking for participantsNCT03784651
What this trial is testing

Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer

Who this might be right for
Bone FractureGlucose, High BloodInsulin Resistance+2 more
Rigshospitalet, Denmark 120
Testing effectiveness (Phase 2)Looking for participantsNCT05455619
What this trial is testing

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Who this might be right for
HR+/HER2-negative Breast CancerMetastatic Breast Cancer
SynDevRx, Inc. 52
Testing effectiveness (Phase 2)Study completedNCT00666666
What this trial is testing

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateStage IV Prostate Cancer
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Study completedNCT01331083
What this trial is testing

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
NCIC Clinical Trials Group 68
Next Page